Back to Search
Start Over
Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
- Source :
-
Journal of Oncology Pharmacy Practice . July2024, Vol. 30 Issue 5, p941-944. 4p. - Publication Year :
- 2024
-
Abstract
- Enfortumab vedotin (EV) is a novel treatment option for patients with advanced/metastatic urothelial carcinoma who have progressed after chemotherapy and immunotherapy. Two patients at two different New England tertiary cancer care centers were treated with EV while concurrently receiving hemodialysis (HD), where a complete response to EV in both patients was noted. The use of EV in patients requiring HD is extrapolated from the available pharmacokinetic and pharmacodynamic literature on monoclonal antibodies in patients requiring HD. There is a paucity of data for the use of antibody-drug conjugates like EV in patients needing dialysis. [ABSTRACT FROM AUTHOR]
- Subjects :
- *THERAPEUTIC use of antineoplastic agents
*THERAPEUTIC use of monoclonal antibodies
*COMBINATION drug therapy
*LIVER tumors
*CYSTOSCOPY
*EDEMA
*IMMUNOTHERAPY
*ANTINEOPLASTIC agents
*HEMODIALYSIS
*ACUTE kidney failure
*POSITRON emission tomography computed tomography
*NEPHRECTOMY
*CHRONIC kidney failure
*MONOCLONAL antibodies
*METASTASIS
*HYDRONEPHROSIS
*TRANSURETHRAL prostatectomy
*COMORBIDITY
ULTRASONIC imaging of the abdomen
BLADDER tumors
Subjects
Details
- Language :
- English
- ISSN :
- 10781552
- Volume :
- 30
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Journal of Oncology Pharmacy Practice
- Publication Type :
- Academic Journal
- Accession number :
- 177899976
- Full Text :
- https://doi.org/10.1177/10781552241237752